Lang NN, Luksha L, Newby DE, Kublickiene K. Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant women.
lieved to play an important role in vascular pathophysiology. It has been suggested to act as a "back-up" mechanism in conditions associated with decreased NO bioavailability, such as heart failure (13, 18) . Furthermore, failure of EDHF to compensate in this way has been implicated in the pathogenesis of preeclampsia (14) .
Despite intensive research, the exact nature of EDHF and its mechanism of action remain unclear. This lack of understanding has precluded its manipulation as a therapeutic target (10) . Multiple candidates have been proposed, but none have been confirmed as a unifying agent constituting EDHF. As such, the term "endothelium-derived hyperpolarizing factor" may be misleading, and EDHF may represent a mechanism rather than a specific factor per se.
The case for gap junctions as a central component of the EDHF mechanism has strengthened (12, 28) . These aqueous pores facilitate the transfer of either small hydrophilic molecules or ionic charge for the conduction of hyperpolarization from the endothelium to smooth muscle and from smooth muscle cell to smooth muscle cell. Gap junctions are composed of two hemi-channels comprising six connexin (Cx) subunits each. Cx37, Cx40, and Cx43 are particularly associated with mammalian endothelium and vascular smooth muscle (12) .
Diverse agents have been employed as putative gap junction blockers, but their other nonspecific, EDHF-independent effects have limited their use. In contrast, the connexin mimetic peptides (CMPs) are highly selective and specific (12, 20) . These short synthetic peptides correspond to conserved amino acid sequences in the first (Gap 26) and second (Gap 27) extracellular loops of Cx37, Cx40, and Cx43 and cause disruption of connexin function (5) .
Pregnancy is associated with a decrease in peripheral vascular resistance and enhanced endothelium-dependent vasodilatation (11) . We have previously reported that EDHF accounts for ϳ50% of endothelium-dependent vasodilatation in these arteries. Furthermore, using the putative gap junction blocker 18␣-glycyrrhetinic acid, our group identified a potential role of gap junctions in EDHF responses (17) . In this study we tested the hypothesis that gap junction blockade with CMPs inhibits EDHF-mediated vasorelaxation in resistance vessels from pregnant women. Furthermore, we examined the expression of the three main vascular connexin subtypes in these vessels. By using CMPs, the current study represents the first assessment of the functional role of gap junctions and their connexin components in EDHF-mediated relaxation in the human vasculature.
MATERIALS AND METHODS
Biopsy collection and vessel preparation. The investigation was undertaken with the approval of the local research ethics committee, with the written informed consent of each patient, and in accordance with the principles outlined in the Declaration of Helsinki. Subcutaneous fat biopsies were obtained from healthy women undergoing elective cesarean section. Women with a history of diabetes mellitus, hypertension, or any other significant past medical history were excluded from participation. Women with abnormal renal or hepatic function also were excluded. Biopsies were taken from the incision margin and immediately placed in cold physiological salt solution (PSS: 119 mmol/l NaCl, 4.7 mmol/l KCl, 2.5 mmol/l CaCl 2, 1.17 mmol/l MgSO4, 25 mmol/l NaHCO3, 1.18 mmol/l KH2PO4, 0.026 mmol/l EDTA, and 5.5 mmol/l glucose).
Resistance arteries were dissected free of surrounding fat and connective tissue and cut into segments ϳ2 mm long. All arteries were kept in PSS at 4°C and used on the day of biopsy. Arteries were mounted in the organ baths of a four-channel wire myograph (multimyograph model 610; Danish Myo Technology, Aarhus, Denmark) as described previously (17) . Each organ bath contained warmed (37°C) PSS and was continuously bubbled with 5% carbon dioxide-95% oxygen. After a 30-min equilibration period, a passive circumference-tension curve was created for each segment to set optimum resting tension. This resting tension is calculated to simulate an in vivo transmural pressure of 100 mmHg. Arteries were then set at 90% of this tension to enable optimal contractile conditions, as described previously (17, 22) . This semiautomated procedure also allows the calculation of arterial diameter. Calibration and data processing were performed using Myodac software (version 2.1; Danish Myo Technology) on a personal computer. All solutions were refreshed every 30 min.
Constriction was elicited using norepinephrine (NE; 3 mol/l). Endothelium-dependent vasodilatation was assessed by the addition of a single dose of bradykinin (BK; 1 mol/l) to each chamber. Arteries that did not achieve at least 60% vasorelaxation to BK were excluded from the study.
Experimental protocols. Arteries were incubated for 40 min in either PSS alone or with the nitric oxide synthase (NOS) inhibitor N -nitro-L-arginine methyl ester (L-NAME; 300 mol/l) and the cyclooxygenase (COX) inhibitor indomethacin (10 mol/l) to block the production of NO and PGI 2, respectively. Arteries were then preconstricted with NE (3 mol/l), and the concentration-response curve for BK (0.001-3 mol/l) was assessed. Arteries then underwent 90 min of incubation with CMPs with or without L-NAME and indomethacin as detailed below. The concentration-response curve to BK was then reassessed. At the end of each experiment, endotheliumindependent vasorelaxation was assessed in response to sodium nitroprusside (SNP; 0.1 mmol/l). The doses of the CMPs used were based on prior published work (4, 12) .
Gap junction inhibition with and without NOS/COX inhibition. Arteries initially incubated in PSS alone were incubated with PSS plus the combined CMPs 37,43 Gap27 (300 mol/l), 40 Gap27 (300 mol/l), and 43 Gap26 (300 mol/l). The contribution of gap junctions to EDHF-mediated vasorelaxation with concurrent NOS/COX inhibition was assessed by preincubating with L-NAME and indomethacin before administering the combined CMPs (as above) in the continued presence of L-NAME and indomethacin.
Contribution of connexin subtypes to EDHF-mediated relaxation. Arteries preincubated with L-NAME and indomethacin alone were incubated with L-NAME and indomethacin plus 1) 37,43 Gap27 plus 40 Gap27 (450 mol/l each), 2) 37,43 Gap27 (900 mol/l), 3) 40 Gap27
(900 mol/l), or 4) 43 Gap26 (900 mol/l). Total peptide concentration in each experiment was kept constant at 900 mol/l.
Effects of 43 Gap26 alone on endothelium-dependent and -independent vasorelaxation. Arteries initially incubated in PSS alone were incubated with 43 Gap26 (900 mol/l) for 90 min. A concentrationresponse curve to BK was constructed (as above) before and after 43 Gap26. In further experiments, a concentration-response curve was constructed for either SNP (0.001-1 mol/l) or the endotheliumindependent, ATP-sensitive potassium channel opener pinacidil (0.001-1 mol/l) before and after incubation with 43 Gap26 (again, without L-NAME and indomethacin).
Immunohistochemistry. Freshly isolated artery segments were cryopreserved in optimal cutting temperature (OCT) compound cooled by liquid nitrogen. Transverse 10-m cryosections were prepared and mounted onto slides, air-dried, and stored at Ϫ20°C. Sections were immunostained with polyclonal rabbit antibodies against mouse connexins [Cx37 and Cx40 (1:50 dilution) or Cx43 (1:100 dilution) at 4°C overnight (Zymed Laboratories, San Francisco, CA)] (15, 23) . Negative control sections were incubated with nonimmune goat IgG (SDS, Falkenberg, Sweden). All slides were counterstained with hematoxylin, dehydrated, and mounted with Pertex (Histolab, Gothenburg, Sweden).
Drugs and chemicals. All drugs and chemicals except the CMPs and antibodies were obtained from Sigma (St. Louis, MO). The CMPs 37,43 Gap27 (SRPTEKTIFII), 40 Gap27 (SRPTEKNVFIV), and 43 Gap26 (VCYDKSFPISHVR) were purchased from American Peptide (Sunnyvale, CA). All drugs except indomethacin and L-NAME were dissolved in PSS before every experiment. Indomethacin was dissolved in pure ethanol. L-NAME was dissolved in distilled water.
Data analysis. All data are expressed as means Ϯ SE. Maximum vasorelaxation (Rmax) is expressed as the percentage return to basal tone produced by the highest concentration of BK (3 mol/l) after NE preconstriction. Analysis of variance (ANOVA) was used to compare paired BK concentration-response curves before and after incubation with CMPs and between groups. Bonferroni's correction for multiple comparisons was used for the analysis of pooled data. Paired Student's t-test was used to compare NE preconstriction before and after incubation with different agents (GraphPad Prism version 4.0). Statistical significance was taken at the 5% level.
RESULTS
Subcutaneous fat biopsy specimens were obtained from 14 pregnant women (5 nulliparous) with a median age of 27 yr (range 25-42 yr) and a median gestational age of 38 wk (range 37-40 wk) undergoing planned cesarean section due to breach presentation (n ϭ 4), previous cesarean section (n ϭ 8), and psychological reasons (n ϭ 2).
A total of 31 arteries dissected from 14 biopsies were included in the experiment. Mean internal diameter of artery segments used was 221 Ϯ 8 m. Vessels with an internal diameter of 100 -300 m were considered to represent resistance arteries, in line with previous definitions (6) . There were no significant differences between artery segments used in each protocol with respect to internal diameter and initial constrictor response to NE (data not shown).
Contribution of EDHF to BK-mediated vasorelaxation. When compared with all arteries incubated in PSS alone (n ϭ 18), incubation with L-NAME and indomethacin (n ϭ 27) reduced maximal vasorelaxation to BK by ϳ50% (R max : 90.3 Ϯ 2.2% in PSS alone vs. 48.1 Ϯ 2.6% with L-NAME and indomethacin, P Ͻ 0.0001). Pilot studies confirmed that BK concentrations of Ͼ3 mol/l failed to further relax vessels incubated in PSS alone.
Gap junction inhibition with the combined CMPs [ 37,43 Gap27 plus 40 Gap27 plus 43 Gap26 (300 mol/l each)] substantially reduced maximal relaxation to BK (R max : 46.6 Ϯ 2.8% with combined CMPs vs. 89.4 Ϯ 3.5% in PSS alone, P ϭ 0.023, n ϭ 6). The inhibition of gap junction-mediated communication with combined CMPs decreased maximal BKinduced vasorelaxation to an extent similar to that of L-NAME plus indomethacin alone (Fig. 1) .
Combined NOS, COX, and gap junction inhibition with the combined CMPs plus L-NAME and indomethacin almost abolished the vasorelaxation to BK (R max : 12.2 Ϯ 3.7% with combined CMPs plus L-NAME and indomethacin vs. 49.0 Ϯ 5.1% with L-NAME and indomethacin, P ϭ 0.0004, n ϭ 6; Fig. 1) .
Contribution of different connexin subtypes to EDHF-mediated vasorelaxation. Incubation with 37,43 Gap27 (450 mol/l) plus 40 Gap27 (450 mol/l) in addition to L-NAME and indomethacin did not reduce maximal vasorelaxation to BK compared with the same vessels incubated in L-NAME and indomethacin alone (R max : 38.2 Ϯ 5.6% with L-NAME and indomethacin plus 37,43 Gap27 and 40 Gap27 vs. 40.6 Ϯ 6.1% with L-NAME and indomethacin, P ϭ 0.319, n ϭ 5; Fig. 2 ).
The addition of 37,43 Gap27 (900 mol/l) or 40 Gap27 (900 mol/l) to L-NAME and indomethacin had no effect on maximal BK-induced vasorelaxation compared with the same arteries incubated with L-NAME and indomethacin alone (R max : 43.6 Ϯ 1.4% with 37, 43 Gap27 plus L-NAME and indomethacin vs. 49.6 Ϯ 4.87% with L-NAME and indomethacin alone, P ϭ 0.39, n ϭ 5; R max : 46.3 Ϯ 5.5% with 40 Gap27 plus L-NAME and indomethacin vs. 45.0 Ϯ 2.2% with L-NAME and indomethacin alone, P ϭ 0.37, n ϭ 4; Fig. 2) . However, the inhibition of Cx43 with 43 Gap26 (900 mol/l) in combination with L-NAME and indomethacin resulted in a marked decrease in maximal vasorelaxation to BK compared with the same arteries incubated with L-NAME and indomethacin alone (R max : 21.0 Ϯ 6.4% with 43 Gap26 plus L-NAME and indomethacin vs. 52.45 Ϯ 8.3% with L-NAME and indomethacin alone, P ϭ 0.0047, n ϭ 5). Maximal BK-induced relaxation after incubation with L-NAME and indomethacin plus 43 Gap26 (900 mol/l) was not different from maximal relaxation after incubation with the three combined CMPs (each at 300 mol/l) (unpaired data, P ϭ 0.397; Fig. 3) .
Effects of 43 Gap26 alone on endothelium-dependent vasorelaxation. Incubation with 43 Gap26 (900 mol/l) (without L-NAME and indomethacin) reduced maximal BK-induced relaxation compared with the same arteries incubated in PSS alone (R max : 40.6 Ϯ 15.8% with 43 Gap26 alone vs. 85.8 Ϯ 5.5% in PSS alone, P ϭ 0.039, n ϭ 5). Maximal BK-induced relaxation after incubation with 43 Gap26 (900 mol/l) alone was not significantly different from that observed after incubation with the three combined CMPs (each at 300 mol/l) in PSS (R max : 40.6 Ϯ 15.8% with 43 Gap26 alone vs. 46.6 Ϯ 2.8% with combined CMPs in PSS, P ϭ 0.69). -nitro-Larginine methyl ester (L-NAME) plus indomethacin (n ϭ 25), or the combined connexin mimetic peptides ( 37,43 Gap27, 40 Gap27, and 43 Gap26 at 300 mol/l each) with or without L-NAME plus indomethacin (n ϭ 6 for both). Indo, indomethacin. *P Ͻ 0.001 vs. PSS. †P Ͻ 0.001 vs. L-NAME and indomethacin alone. Fig. 2 . Concentration-response curves for BK in subcutaneous arteries incubated in PSS (n ϭ 18), L-NAME and indomethacin alone (n ϭ 25), or L-NAME and indomethacin plus 37,43 Gap27 and 40 Gap27 combined (450 mol/l each; n ϭ 5), 37, 43 Gap27 alone (900 mol/l; n ϭ 5), or 40 Gap27 alone (900 mol/l; n ϭ 4). P Ͼ 0.05, L-NAME and indomethacin alone vs. L-NAME and indomethacin in combination with 37, 43 Gap27 and/or 40 Gap27; ns, not significant.
Endothelium-independent vasorelaxation and vasoconstriction.
Relaxation evoked by the exogenous NO donor SNP (0.1 mmol/l) was unaffected throughout all studies (data not shown). NE induced vasoconstriction of 2.1 Ϯ 0.07 mN/mm 2 and was unaffected by any of the incubation protocols. 43 Gap26 alone had no effect on responses to the endotheliumindependent vasodilators SNP and pinacidil (n ϭ 5 for both) (Fig. 4) .
Immunohistochemistry. Immunohistochemistry demonstrated the consistent presence of Cx37, Cx40, and Cx43 in arterial segments (Fig. 5) . Connexins 37, 40, and 43 were seen in both vascular smooth muscle and endothelial cells, although Cx40 was predominantly found in the endothelium.
DISCUSSION
We have made the first assessment of the role of gap junctions and connexin subtypes in EDHF-mediated vasorelaxation of human arteries by using highly specific gap junction inhibitors. We have shown that EDHF-mediated vasorelaxation relies on gap junction communication acting principally through the Cx43 subtype.
We have confirmed that subcutaneous resistance arteries obtained from pregnant women retain ϳ50% of their endothelium-dependent relaxant capacity after the inhibition of endothelial NO and PGI 2 synthesis with L-NAME and indomethacin, respectively. This L-NAME-and indomethacin-insensitive component of endothelium-dependent vasorelaxation is widely regarded to reflect EDHF activity. Furthermore, incubation , and pinacidil (C) in subcutaneous arteries incubated in PSS and 43 Gap26 (900 mol/l) (n ϭ 5 for each). *P Ͻ 0.05 vs. PSS. Fig. 3 . Concentration-response curves for BK in subcutaneous arteries incubated in PSS (n ϭ 18), L-NAME and indomethacin alone (n ϭ 25), or L-NAME and indomethacin plus 37,43 Gap27, 40 Gap27, and 43 Gap26 combined (300 mol/l each; n ϭ 6) or 43 Gap26 alone (900 mol/l; n ϭ 5). *P Ͻ 0.001; †P Ͻ 0.005 vs. L-NAME and indomethacin alone.
with a combination of 37, 43 Gap27, 40 Gap27, and 43 Gap26 (300 mol/l each) attenuated vasorelaxation to BK to a similar extent as L-NAME and indomethacin alone and revealed that gap junctions are required for ϳ50% of BK-induced vasorelaxation.
Coincubation of the triple CMP combination with L-NAME and indomethacin virtually abolished BK-induced vasorelaxation. That is, the L-NAME/indomethacin-insensitive component of BK-induced relaxation was inhibited by gap junction blockade. This provides further evidence of a pivotal role for gap junctions in EDHF-mediated relaxation in these vessels. These findings are in keeping with our group's previous study (17) in which BK-mediated relaxation was abolished by a combination of L-NAME, indomethacin, and 18␣-glycyrrhetinic acid.
We went on to assess the effects of each of the three CMPs to infer the relative functional importance of Cx37, Cx40, and Cx43.
43 Gap26 exerted marked inhibition of EDHF-mediated relaxation to BK. Indeed, at 900 mol/l, its inhibitory effect did not differ from that seen after incubation with the triple combination of CMPs. The marked inhibition of vasodilatation achieved by incubation with 43 Gap26 contrasts with the lack of inhibition seen after incubation with 37,43 Gap27 and 40 Gap27 in combination (450 mol/l each) and individually (900 mol/l). Furthermore, in the absence of L-NAME and indomethacin, 43 Gap26 caused a significant attenuation in maximal vasodilatation to BK. Together, these findings suggest that the combined inhibitory effect of all three CMPs is derived predominantly from 43 Gap26 activity and implicate Cx43 as the dominant connexin isoform involved in the mediation of EDHF responses in these vessels.
Data from combined endothelial NOS/COX knockout mice imply a greater role for EDHF in females than in males (29) , whereas other animal models have demonstrated dynamic Cx43 expression under the influence of estrogen. Pregnant rats exhibit enhanced EDHF-mediated vasodilatation and upregulation of vascular Cx43 expression (8) . These effects are markedly diminished in ovariectomized animals but can be restored by exogenous estrogen supplementation (16) . Furthermore, an increase in Cx43 expression in response to increased shear stress and mechanical load has been demonstrated (26) . The rise in circulating blood volume associated with normal human pregnancy could invoke similar changes in Cx43 expression and function and account for the predominant func- tional importance of Cx43 in our study. Although diversity exists between species and the sexes, EDHF makes a large contribution to endothelium-dependent vasodilatation in various vascular beds in men and nonpregnant women (3, 7, 21, 24, 25, 30, 31) . The present study supports a clear role for Cx43 in vascular responses of pregnant women (8) . Whether Cx43 is of such fundamental importance in men and nonpregnant women and in other vascular beds remains to be established.
The interpretation of results using older putative gap junction blockers has been limited by their nonspecific effects. Indeed, 18␣-glycyrrhetinic acid can affect ion channel conduction to attenuate endothelial cell hyperpolarization directly. Confidence in the CMPs is growing: they do not suppress endothelial hyperpolarization directly and do not exert nongap-junctional effects (12, 19) . Their exact mechanism of action remains unclear, but they are thought to interfere with connexin-gating properties. Unlike 18␣-glycyrrhetinic acid, they do not affect the structural integrity, number, or distribution of connexins (1) . When administered in combination and individually in this study, the CMPs did not have any influence on vasorelaxation to SNP or preconstriction to NE, suggesting that they specifically inhibit endothelium-dependent vasorelaxation without interfering with vascular smooth muscle function. Whereas 43 Gap26 alone significantly attenuates maximal relaxation to BK, it did not have any influence on the concentration-response curve obtained after exposure to the endothelium-independent vasodilators SNP and pinacidil. This provides more robust evidence that this CMP does not exert nonspecific or toxic effects on smooth muscle function.
If Cx43 has a dominant role, then one might expect EDHFmediated vasorelaxation to be inhibited by 37, 43 Gap27 as well as 43 Gap26. 37,43 Gap27 shares sequence homology with the Gap27 domain of both Cx37 and Cx43, whereas 43 Gap26 shares homology with the Gap26 domain of Cx43 only. Both 37,43 Gap27 and 43 Gap26 have been shown to act in a connexinspecific manner (1, 5), but our findings concur with others who have reported differential activity between these two CMPs. In 2003, Chaytor et al. (4) reported that 37,43 Gap27 and 40 Gap27 partially inhibited the transmission of hyperpolarization from endothelium to smooth muscle in the rabbit iliac artery. However, the addition of 43 Gap26 was required to abolish this phenomenon completely, implying that 37,43 Gap27 causes incomplete inhibition of Cx43 (4) . Because each of these peptides shares homology with different extracellular loops, these data suggest that targeting 37,43 Gap27 and 43 Gap26 vary in their propensity to inhibit Cx43 by acting at different sites. It is unclear whether Gap26 plays a greater role than Gap27 in Cx43 gating and/or docking.
Immunohistochemistry revealed Cx37 and Cx43 expression in both the endothelium and smooth muscle. Cx40 was also seen in these cells, but expression was predominantly seen in the endothelium. Although myoendothelial gap junctions are proposed to allow the transfer of hyperpolarization generated in the endothelium to the underlying smooth muscle, homocellular gap junctions between adjacent smooth muscle or endothelial cells are also an ideal conduit for the longitudinal conduction of hyperpolarization and coordinated regulation of vascular tone. Indeed, mice genetically engineered to lack vascular Cx40 display not only hypertension but also irregular vasomotion (9). Our own study has not differentiated whether the inhibition of EDHF-mediated vasodilatation is due to the inhibition of Cx43 in myoendothelial junctions, in homocellular junctions, or in both. Irrespective, we have demonstrated a critical role for this connexin in endothelium-dependent vasorelaxation. Furthermore, we have shown that endotheliumindependent vasorelaxation is unaffected by gap junction and, specifically, Cx43 inhibition.
In summary, we have shown that EDHF accounts for ϳ50% of BK-induced vasorelaxation in resistance arteries from pregnant women. Using CMPs, we have provided functional evidence that EDHF mediates its vasorelaxatory actions via gap junctions. We have demonstrated the expression of three major connexin isoforms and highlighted a predominant functional role for Cx43 in the mediation of EDHF responses in this vascular bed. The extension of these studies to men, nonpregnant women, and pathophysiological states warrants further investigation. 
